ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University
[Anwulignan inhibits malignant phenotypes of gastric cancer cells by antagonizing activation of the JAK1/STAT3 signaling pathway].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
methodsTo evaluate the inhibitory effect of anwulignan (ANW) on malignant biological behaviors of gastric cancer cells and explore its underlying molecular mechanism.
methodsThe inhibitory effect of ANW on viability and proliferation of gastric cancer HGC-27 and SGC-7901 cells were evaluated using CCK-8 assay, EdU staining and colony formation assay. In a nude mouse model bearing gastric cancer xenografts, the effect of ANW on tumor cell proliferation was examined using immunohistochemistry for Ki-67. The changes in cell cycle, apoptosis, migration, invasion, and expressions of MMPs and epithelial-mesenchymal transition (EMT) markers following ANW treatment were detected using flow cytometry, TUNEL staining, Western blotting, Transwell assay, and qPCR. The role of the JAK1/STAT3 signaling pathway in mediating the anti-tumor activity of ANW was validated by detecting JAK1/STAT3 phosphorylation, pathway activation and siRNA-mediated JAK1 knockdown experiments.
resultsIn HGC-27 and SGC-7901 cells, ANW dose-dependently suppressed cell proliferation and colony formation, induced G1 cell cycle arrest, and downregulated the expressions of cyclin D1/CDK2 and P53. ANW treatment significantly inhibited tumor growth and decreased Ki-67 positivity in the mouse xenografts. ANW effectively promoted cell apoptosis, suppressed Bcl-2 expression, upregulated cleaved caspase-3 and Bax expressions, inhibited migration and invasion, lowered MMP-2/MMP-9 expressions, and blocked EMT progression in gastric cancer cells. Mechanistically, ANW significantly inhibited JAK1/STAT3 phosphorylation, while the JAK1/STAT3 activator RO8191 reversed the anti-tumor effect of ANW; JAK1 knockdown mimicked and enhanced the inhibitory effect of ANW on gastric cancer cells. ANW significantly inhibited EMT in the mouse xenografts, and this effect was attenuated by RO8191 treatment.
conclusionsANW inhibits malignant phenotype of gastric cancer cells by inhibiting the activation of the JAK1/STAT3 signaling pathway, thereby inducing cell cycle arrest, promoting apoptosis, and suppressing EMT and MMP-mediated invasion and migration, suggesting the potential of ANW as a therapeutic agent for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.